Patients with pulmonary fibrosis who took the AI-developed drug Rentosertib saw their estimated biological age drop, according to a study published in Nature Biotechnology. Rentosertib (ISM001-055) is an experimental treatment for idiopathic pulmonary fibrosis, created by Insilico Medicine.

What Happened

The study tracked a decrease in estimated biological age among patients treated with Rentosertib. The drug is still experimental and is being developed specifically for idiopathic pulmonary fibrosis.

How the Molecule Was Created

AI played a central role at both key stages: the PandaOmics platform identified the therapeutic target—the TNIK protein—while the generative Chemistry42 platform designed the Rentosertib molecule to interact with that target.

Why It Matters

These peer-reviewed results highlight a real-world use case for AI in drug development, from target selection to molecule design. The drop in estimated biological age among pulmonary fibrosis patients points to the potential of this approach for creating new therapeutic solutions.